Search Results - "Tremblay, Douglas"

Risk factors and outcomes of COVID‐19 in New York City; a retrospective cohort study by Gerwen, Maaike, Alsen, Mathilda, Little, Christine, Barlow, Joshua, Genden, Eric, Naymagon, Leonard, Tremblay, Douglas

“…Coronavirus disease 2019 (COVID‐19) is a global pandemic and information on risk factors for worse prognosis is needed to accurately identify patients at risk…”
Get full text

Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study by Tremblay, Douglas, van Gerwen, Maaike, Alsen, Mathilda, Thibaud, Santiago, Kessler, Alaina, Venugopal, Sangeetha, Makki, Iman, Qin, Qian, Dharmapuri, Sirish, Jun, Tomi, Bhalla, Sheena, Berwick, Shana, Feld, Jonathan, Mascarenhas, John, Troy, Kevin, Cromwell, Caroline, Dunn, Andrew, Oh, William K., Naymagon, Leonard

“…Tremblay and colleagues asked whether patients receiving either routine anticoagulation or antiplatelet therapy for existing conditions prior to becoming ill…”
Get full text

Next Generation Therapeutics for the Treatment of Myelofibrosis by Tremblay, Douglas, Mascarenhas, John

“…Myelofibrosis is a myeloproliferative neoplasm characterized by splenomegaly, constitutional symptoms, bone marrow fibrosis, and a propensity towards…”
Get full text

The role of anticoagulation in pylephlebitis: a retrospective examination of characteristics and outcomes by Naymagon, Leonard, Tremblay, Douglas, Schiano, Thomas, Mascarenhas, John

“…Pylephlebitis, or suppurative thrombophlebitis of the portal vein, typically occurs in the context of an intraabdominal infection or abdominal sepsis…”
Get full text

Contemporary and future strategies in polycythemia vera by Waksal, Julian A., Tremblay, Douglas A.

“…Polycythemia vera (PV) is characterized by clonal proliferation of a hematopoietic stem cell leading to erythrocytosis. Patients with PV have significantly…”
Get full text

Outcomes of Patients With Hypothyroidism and COVID-19: A Retrospective Cohort Study by van Gerwen, Maaike, Alsen, Mathilda, Little, Christine, Barlow, Joshua, Naymagon, Leonard, Tremblay, Douglas, Sinclair, Catherine F, Genden, Eric

“…Coronavirus diseases (COVID-19) is associated with high rates of morbidity and mortality and worse outcomes have been reported for various morbidities. The…”
Get full text

Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies by Zahr, Abdallah Abou, Salama, Mohamed E, Carreau, Nicole, Tremblay, Douglas, Verstovsek, Srdan, Mesa, Ruben, Hoffman, Ronald, Mascarenhas, John

“…Bone marrow fibrosis is a central pathological feature and World Health Organization major diagnostic criterion of myelofibrosis. Although bone marrow fibrosis…”
Get full text

Conventional Cytogenetic Analysis and Array CGH + SNP Identify Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis Patients Who Are at Risk for Disease Progression by Tripodi, Joseph, Hoffman, Ronald, Tremblay, Douglas, Ahire, Daiva, Mascarenhas, John, Kremyanskaya, Marina, Najfeld, Vesna

“…The Philadelphia chromosome-negative myeloproliferative neoplasms (Ph-MPNs) are a heterogeneous group of clonal hematopoietic malignancies that include…”
Get full text

The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis by Naymagon, Leonard, Tremblay, Douglas, Zubizarreta, Nicole, Moshier, Erin, Troy, Kevin, Schiano, Thomas, Mascarenhas, John

“…Guidelines currently favor vitamin K antagonists or low-molecular-weight heparins for treatment of noncirrhotic portal vein thrombosis (ncPVT). Use of direct…”
Get full text

Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study by Schmidt, Andrew L., Bakouny, Ziad, Bhalla, Sheena, Steinharter, John A., Tremblay, Douglas A., Awad, Mark M., Kessler, Alaina J., Haddad, Robert I., Evans, Michelle, Busser, Fiona, Wotman, Michael, Curran, Catherine R., Zimmerman, Brittney S., Bouchard, Gabrielle, Jun, Tomi, Nuzzo, Pier V., Qin, Qian, Hirsch, Laure, Feld, Jonathan, Kelleher, Kaitlin M., Seidman, Danielle, Huang, Hsin-Hui, Anderson-Keightly, Heather M., Abou Alaiwi, Sarah, Rosenbloom, Talia D., Stewart, Penina S., Galsky, Matthew D., Choueiri, Toni K., Doroshow, Deborah B.

Get full text

Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor by Tremblay, Douglas, Dougherty, Mikaela, Mascarenhas, John, Gallagher, Emily Jane

“…Weight gain is a known adverse effect of ruxolitinib, a JAK1/2 inhibitor that is the mainstay of treatment for many patients with myelofibrosis. The mechanisms…”
Get full text

Evaluation of Therapeutic Strategies to Reduce the Number of Thrombotic Events in Patients With Polycythemia Vera and Essential Thrombocythemia by Tremblay, Douglas, Kosiorek, Heidi E, Dueck, Amylou C, Hoffman, Ronald

“…Thrombosis is the largest contributor to morbidity and mortality in patients with polycythemia vera (PV) and essential thrombocythemia (ET). Our understanding…”
Get full text

How to customize common data models for rare diseases: an OMOP-based implementation and lessons learned by Ahmadi, Najia, Zoch, Michele, Guengoeze, Oya, Facchinello, Carlo, Mondorf, Antonia, Stratmann, Katharina, Musleh, Khader, Erasmus, Hans-Peter, Tchertov, Jana, Gebler, Richard, Schaaf, Jannik, Frischen, Lena S, Nasirian, Azadeh, Dai, Jiabin, Henke, Elisa, Tremblay, Douglas, Srisuwananukorn, Andrew, Bornhäuser, Martin, Röllig, Christoph, Eckardt, Jan-Niklas, Middeke, Jan Moritz, Wolfien, Markus, Sedlmayr, Martin

“…Given the geographical sparsity of Rare Diseases (RDs), assembling a cohort is often a challenging task. Common data models (CDM) can harmonize disparate…”
Get full text

Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation by Phelan, Rachel, Im, Annie, Hunter, Rebecca L., Inamoto, Yoshihiro, Lupo-Stanghellini, Maria Teresa, Rovo, Alicia, Badawy, Sherif M., Burns, Linda, Eissa, Hesham, Murthy, Hemant S., Prasad, Pinki, Sharma, Akshay, Suelzer, Elizabeth, Agrawal, Vaibhav, Aljurf, Mahmoud, Baker, Karen, Basak, Grzegorz W., Buchbinder, David, DeFilipp, Zachariah, Grkovic, Lana Desnica, Dias, Ajoy, Einsele, Hermann, Eisenberg, Michael L., Epperla, Narendranath, Farhadfar, Nosha, Flatau, Arthur, Gale, Robert Peter, Greinix, Hildegard, Hamilton, Betty K., Hashmi, Shahrukh, Hematti, Peiman, Jamani, Kareem, Maharaj, Dipnarine, Murray, John, Naik, Seema, Nathan, Sunita, Pavletic, Steven, Peric, Zinaida, Pulanic, Drazen, Ross, Richard, Salonia, Andrea, Sanchez-Ortega, Isabel, Savani, Bipin N., Schechter, Tal, Shah, Ami J., Smith, Stephanie M., Snowden, John A., Steinberg, Amir, Tremblay, Douglas, Vij, Sarah C., Walker, Lauren, Wolff, Daniel, Yared, Jean A., Schoemans, Hélène, Tichelli, André

“…Male-specific late effects after hematopoietic cell transplantation (HCT) include genital chronic graft-versus-host disease (GvHD), hypogonadism, sexual…”
Get full text

Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study by Bhalla, Sheena, Bakouny, Ziad, Schmidt, Andrew L., Labaki, Chris, Steinharter, John A., Tremblay, Douglas A., Awad, Mark M., Kessler, Alaina J., Haddad, Robert I., Evans, Michelle, Busser, Fiona, Wotman, Michael, Curran, Catherine R., Zimmerman, Brittney S., Bouchard, Gabrielle, Jun, Tomi, Nuzzo, Pier V., Qin, Qian, Hirsch, Laure, Feld, Jonathan, Kelleher, Kaitlin M., Seidman, Danielle, Huang, Hsin-Hui, Anderson-Keightly, Heather M., El Zarif, Talal, Abou Alaiwi, Sarah, Rosenbloom, Talia D., Stewart, Penina S., Galsky, Matthew D., Choueiri, Toni K., Doroshow, Deborah B.

“…•Patients with lung cancer faced significant cancer care disruptions due to COVID-19.•Patients with lung cancer were at greater risk for pandemic-related care…”
Get full text

Convalescent Plasma for the Treatment of Severe COVID‐19 Infection in Cancer Patients by Tremblay, Douglas, Seah, Carina, Schneider, Thomas, Bhalla, Sheena, Feld, Jonathan, Naymagon, Leonard, Wang, Bo, Patel, Vaibhav, Jun, Tomi, Jandl, Thomas, Rahman, Farah, Liu, Sean T. H., Aberg, Judith A., Bouvier, Nicole

“…Background Patients with malignancy are particularly vulnerable to infection with Severe Acute Respiratory Disease‐Coronavirus‐2 (SARS‐CoV‐2) given their…”
Get full text

Prevalence of Cytopenia in the General Population-A National Health and Nutrition Examination Survey Analysis by Alpert, Naomi, Rapp, Joseph L, Mascarenhas, John, Scigliano, Eileen, Tremblay, Douglas, Marcellino, Bridget K, Taioli, Emanuela

“…Cytopenia, a reduced count of blood cells manifesting as anemia, neutropenia, and/or thrombocytopenia is frequently associated with other medical conditions…”
Get full text

PB2231: AN OVERLOOKED MIMIC? AUTOIMMUNE MYELOFIBROSIS ‐ A SCOPING REVIEW OF THE LITERATURE by Riazat‐Kesh, Yosef Joseph Rene Amel, Maraveyas, Alexander, Martin, Lily, Tremblay, Douglas

Get full text

Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies by Feld, Jonathan, Tremblay, Douglas, Dougherty, Mikaela, Czaplinska, Tina, Sanchez, Gillian, Brady, Claudia, Kremyanskaya, Marina, Bar‐Natan, Michal, Keyzner, Alla, Marcellino, Bridget K., Gabrilove, Janice, Navada, Shyamala C., Silverman, Lewis R., El Jamal, Siraj M., Mascarenhas, John, Shih, Alan H.

“…Hypomethylating agents (HMAs) in combination with venetoclax have been widely adopted as the standard of care for patients who cannot tolerate induction…”
Get full text

Mild anemia as a single independent predictor of mortality in patients with COVID‐19 by Tremblay, Douglas, Rapp, Joseph L., Alpert, Naomi, Lieberman‐Cribbin, Wil, Mascarenhas, John, Taioli, Emanuela, Ghaffari, Saghi

“…The coronavirus disease 2019 (COVID‐19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) has led to an unprecedented international health…”
Get full text